Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)

Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumors. However, there are some special situations tha...

Full description

Bibliographic Details
Authors: Gonzalez Cao, Maria, Puertolas, Teresa, Riveiro, Mar, Muñoz Couselo, Eva, Ortiz, Carolina, Paredes, Roger, Podzamczer Palter, Daniel, Manzano, Jose Luis, Molto, Jose, Revollo, Boris, Carrera Álvarez, Cristina, Mateu, Lourdes, Fancelli, Sara, Espinosa, Enrique, Clotet, Bonaventura, 1953-, Martínez Picado, Francisco Javier, Cerezuela, Pablo, Soria, Ainara, Marquez, Ivan, Mandala, Mario, Berrocal, Alfonso, Spanish Melanoma Group (GEM).
Format: article
Status:Published version
Publication Date:2021
Country:España
Institution:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repository:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/176933
Online Access:https://hdl.handle.net/2445/176933
Access Level:Open access
Keyword:Melanoma
Immunoteràpia
Càncer
Immunotheraphy
Cancer
Description
Summary:Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumors. However, there are some special situations that could be a challenge for clinical management. Persons with chronic infections, such as HIV-1 or viral hepatitis, latent tuberculosis, or a history of solid organ transplantation, could be candidates for cancer immunotherapy, but their management requires a multidisciplinary approach. The Spanish Melanoma Group (GEM) panel in collaboration with experts in virology and immunology from different centers in Spain reviewed the literature and developed evidence-based guidelines for cancer immunotherapy management in patients with chronic infections and immunosuppression. These are the first clinical guidelines for cancer immunotherapy treatment in special challenging populations. Cancer immunotherapy in chronically infected or immunosuppressed patients is feasible but needs a multidisciplinary approach in order to decrease the risk of complications related to the coexistent comorbidities.

Similar Items